Loading...
•
Jun 30, 2020
CorMedix Q2 2020 Earnings Report
Reported a net loss due to increased expenses related to preparations for Defencath’s commercial launch.
Key Takeaways
CorMedix reported a net loss of $3.8 million, or $0.14 per share, for the second quarter of 2020, compared to a net loss of $0.7 million, or $0.03 per share, in the second quarter of 2019. The increased loss was attributed to higher expenses related to the commercial launch of Defencath.
Completed rolling submission for Defencath.
Completed an institutional financing to broaden investment banking relationships.
Preparing for the launch of Defencath in the U.S. hemodialysis market following FDA approval.
Operating expenses increased by approximately 61% to $8.9 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...